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Polyunsaturated fatty acids and prostate
cancer risk: a Mendelian randomisation
analysis from the PRACTICAL consortium
Nikhil K Khankari1, Harvey J Murff1, Chenjie Zeng1, Wanqing Wen1, Rosalind A Eeles2,3, Douglas F Easton4,
Zsofia Kote-Jarai2, Ali Amin Al Olama4, Sara Benlloch4, Kenneth Muir5, Graham G Giles6,7, Fredrik Wiklund8,
Henrik Gronberg8, Christopher A Haiman9, Johanna Schleutker10,11, Børge G Nordestgaard12, Ruth C Travis13,
Jenny L Donovan14, Nora Pashayan4,15, Kay-Tee Khaw16, Janet L Stanford17,18, William J Blot19,
Stephen N Thibodeau20, Christiane Maier21,22, Adam S Kibel23,24, Cezary Cybulski25, Lisa Cannon-Albright26,
Hermann Brenner27,28, Jong Park29, Radka Kaneva30, Jyotsna Batra31, Manuel R Teixeira32,33,
Hardev Pandha34, Wei Zheng*,1 and the PRACTICAL consortium35
Background: Prostate cancer is a common cancer worldwide with no established modifiable lifestyle factors to guide prevention.
The associations between polyunsaturated fatty acids (PUFAs) and prostate cancer risk have been inconsistent. Using Mendelian
randomisation, we evaluated associations between PUFAs and prostate cancer risk.
Methods: We used individual-level data from a consortium of 22 721 cases and 23 034 controls of European ancestry. Externally-
weighted PUFA-specific polygenic risk scores (wPRSs), with explanatory variation ranging from 0.65 to 33.07%, were constructed
and used to evaluate associations with prostate cancer risk per one standard deviation (s.d.) increase in genetically-predicted
plasma PUFA levels using multivariable-adjusted unconditional logistic regression.
Results: No overall association was observed between the genetically-predicted PUFAs evaluated in this study and prostate
cancer risk. However, risk reductions were observed for short-chain PUFAs, linoleic (ORLA¼ 0.95, 95%CI¼ 0.92, 0.98) and
a-linolenic acids (ORALA¼ 0.96, 95%CI¼ 0.93, 0.98), among men o62 years; whereas increased risk was found among men X62
years for LA (ORLA¼ 1.04, 95%CI¼ 1.01, 1.07). For long-chain PUFAs (i.e., arachidonic, eicosapentaenoic, and docosapentaenoic
acids), increased risks were observed among men o62 years (ORAA¼ 1.05, 95%CI¼ 1.02, 1.08; OREPA¼ 1.04, 95%CI¼ 1.01, 1.06;
ORDPA¼ 1.05, 95%CI¼ 1.02, 1.08).
Conclusion: Results from this study suggest that circulating o-3 and o-6 PUFAs may have a different role in the aetiology of early-
and late-onset prostate cancer.
Prostate cancer is the most common cancer among Caucasian men
worldwide (Torre et al, 2015). Identifying modifiable prostate
cancer risk factors could help to alleviate the burden of prostate
cancer. However, little is known about modifiable factors for this
common cancer.
Several previous epidemiologic studies have examined the
relation between polyunsaturated fatty acids (PUFAs) and prostate
cancer risk (Zock and Katan, 1998; Carayol et al, 2010; Sakai et al,
2012; Alexander et al, 2015). Given the possible role that PUFAs
may have in prostate carcinogenesis, with suggested anti-
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inflammatory effects for o-3 PUFAs and inflammatory effects for
o-6 PUFAs (Berquin et al, 2011), an examination of these
nutritional factors may be warranted. Specifically, metabolism of
o-6 PUFAs via the cyclooxygenase-2 enzyme results in the
production of inflammatory mediators including prostaglandin E2
that has been reported to affect prostate carcinogenesis (Sobolewski
et al, 2010). Others include the lipoxygenase and cytochrome p450
pathways producing leukotrienes and hydroxyeicosatetraenoic
acids, which have also been implicated in cancer development
(Panigrahy et al, 2010; Wang and Dubois, 2010). On the contrary,
products of o-3 PUFA metabolism via these same biologic
pathways have demonstrated anti-inflammatory properties
(Chapkin et al, 2009). However, the association between PUFAs
and prostate cancer risk is not supported by a recent meta-analysis
summarising prospective studies of long-chain o-3 PUFA intake
and prostate cancer incidence that reported null results for both
self-reported dietary intakes and biomarker measures of PUFAs
(Alexander et al, 2015). Observational studies of dietary factors and
cancer risk are prone to biases, including confounding, selection
bias, measurement error, and reverse causation. Measurement
error is an important limitation for studies examining diet via food
frequency questionnaires. Although biomarker PUFA measure-
ments may provide an objective measure of intake, depending on
the biomarker used (i.e., serum vs red blood cell) the time period of
exposure will vary (Arab, 2003), and thus an objective PUFA
measurement may not represent the relevant aetiologic time
period. As a result, reverse causation in studies of prostate cancer
and diet (regardless of whether diet was measured via food
frequency questionnaire or biomarkers) may be of particular
concern, given the slow growth of most prostate tumours and the
prospect that men diagnosed with low risk (i.e., low volume and
grade) disease may not be treated for several years in accord with
current treatment guidelines. Given these potential limitations of
observational studies the estimation of an unbiased (potentially
causal) association may be difficult.
Mendelian randomisation is based on the principle of random
assortment of alleles at conception, and may identify causal risk
factors for disease by utilising a number of genetic variants (also
known as the genetic instrument) as a proxy for an exposure.
Previous genome-wide association studies (GWAS) have identified
several variants that together explain a large proportion of
variation in PUFA levels, thus making them a potential candidate
for Mendelian randomisation analysis.
We sought to identify potentially causal associations between
genetically-predicted plasma PUFA levels and risk of developing
prostate cancer using case–control data from a large consortium.
In our Mendelian randomisation analysis, we examined the main
o-3 and o-6 PUFAs, including: (1) o-6 PUFAs: linoleic acid
(LA) and arachidonic acid (AA); and (2) o-3 PUFAs: a-linolenic
acid (ALA), eicosapentaenoic acid (EPA), docosapentaenoic acid
(DPA), and docosahexaenoic acid (DHA).
MATERIALS AND METHODS
Study population. We used the resources of the Prostate Cancer
Association Group to Investigate Cancer Associated Alterations in
the Genome (PRACTICAL), a large consortium of prostate cancer
genetic association studies (Eeles et al, 2013). In our analysis, we
excluded those individuals who were not of European ancestry
(n¼ 1189) and all individuals from the Washington University
Genetics Study (WUGS) case-only study (n¼ 944) and the
Prostate Cancer Mechanisms of Progression and Treatment
(PrOMPT) study that had only two controls (n¼ 168). The final
analytic data set consisted of 45 755 individuals (22 721 cases and
23 034 controls).
Instrumental variables. We used results from published GWAS
conducted by the Cohorts for Heart and Aging Research in
Genomic Epidemiology (CHARGE) consortium examining plasma
levels of o-6 (Guan et al, 2014) and o-3 (Lemaitre et al, 2011)
PUFAs in order to identify genetic variants associated with plasma
PUFA levels. We also considered several variants identified from
the metabolomics literature; however, many of these single-
nucleotide polymorphisms (SNPs) were either the same or in high
linkage disequilibrium with those reported in the two CHARGE
GWAS. Therefore, in total we identified 23 SNPs associated with
any PUFA trait from these two published GWAS. Of these, 14 were
associated with the essential PUFAs (i.e., LA, AA, ALA, EPA, DPA,
and DHA). Finally, 9 of these 14 SNPs were independent
(r2 o0.1), and thus were used in the genetic instrument for the
Mendelian randomisation analyses. Please refer to Supplementary
Figure 1 for a summary of SNP selection.
For each variant selected, the allele that was associated with
increased levels of plasma PUFAs was considered the effect allele,
and the summary statistics for these effect alleles were obtained
from published PUFA GWAS (Lemaitre et al, 2011; Guan et al,
2014). Two of these selected variants (rs174547 and rs16966952)
were associated with multiple PUFAs and, thus, were not exclusive
to any particular genetic instrument.
Genotyping and imputation. The PRACTICAL study samples
were genotyped using a custom Illumina Infinium array (iCOGS)
as part of the Collaborative Oncological Gene-environment Study
(COGS), including 485 000 prostate cancer-related SNPs selected
from four previous GWAS (UKGPCS, CGEMS, BPC3, and CAPS),
fine mapping of known prostate cancer susceptibility regions at the
time of custom chip design, and from candidate gene studies
examining important biologic pathways (including hormone
metabolism, cell cycle, and DNA repair) (Eeles et al, 2013).
Standard quality control protocols were followed by excluding
individuals with genotyping call rates o95%, heterozygosity
greater than or less than 4.89 standard deviations from the
ethnicity-specific mean, duplicates, and relative pairs (Eeles et al,
2013; Al Olama et al, 2014). Single-nucleotide polymorphisms with
call rates o95% were excluded, as well as those deviating from
Hardy–Weinberg Equilibrium in the controls at P-value
o1 10 7 (Eeles et al, 2013; Al Olama et al, 2014). Of the nine
SNPs associated with PUFAs included in our analysis, three were
directly genotyped (rs780094, rs2236212, and rs174538) and six
were imputed (rs3734398, rs3798713, rs1074011, rs174547,
rs2727270, and rs1696695) with high quality (r2 40.76). Single-
nucleotide polymorphisms were imputed in two stages; first using
SHAPEIT (http://www/shapeit.fr/) by chromosome and chunk,
and then data were phased with the haplotypes from 1000
Genomes Phase 3 (March 2012 release) which were then used for
imputation using IMPUTE.V2 (https://mathgen.stats.ok.ac.uk/
impute/impute_v2.html) (Eeles et al, 2013; Al Olama et al, 2014).
Weighted-polygenic risk scores. For analyses using individual-
level data, an externally weighted-polygenic risk score (wPRS) was
constructed for each PUFA separately using the SNPs associated
with that fatty acid. Allele dosage was used for imputed SNPs.
Using this information, PUFA-specific wPRSs were constructed
per individual where effect alleles were weighted according to their
published associations from PUFA GWAS (Lemaitre et al, 2011;
Guan et al, 2014), as follows:
Xn
i¼1
biSNPi;
where SNPi represents the effect allele dosage and bi represents the
increase in PUFA levels (as a percentage of total plasma fatty acids)
for that specific variant, summed across each of the n variants used
in the PUFA-specific wPRSs. Thus, the wPRS represents an
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increase in PUFA levels measured as a percentage of total plasma
fatty acids. The GWAS summary statistics for the association
between each variant and PUFA trait are listed in Table 1. The
theoretical maximum value for each PUFA-specific wPRS was 5.53,
3.78, 0.03, 0.24, 0.26, 0.23, for LA, AA, ALA, EPA, DPA, and DHA,
respectively. The theoretical maximum value for each PUFA-
specific wPRS per individual was calculated by taking the sum of
the product of the GWAS effect allele summary estimate and
the maximum number of effect alleles per SNP included in
each PUFA-specific instrument (e.g., maximum wPRS for
AA¼ (1.691 2)þ (0.199 2)¼ 3.78).
Statistical analyses. Unconditional logistic regression was used to
estimate associations between genetically-predicted PUFA levels
(wPRSs) and risk of prostate cancer per one standard deviation
increase in predicted fatty acid levels. All models were adjusted for
age, eight principal components for European ancestry, and
PRACTICAL study site. We further assessed the relation between
wPRS and prostate cancer risk using restricted cubic splines for
those polygenic risk scores including more than one variant
(LA, AA, EPA, DPA). Supplementary Figures 2–5 display the
shape of the dose response between the wPRS and log-odds of
prostate cancer from restricted cubic spline models suggesting
non-linearity (Desquilbet and Mariotti, 2010).
We also conducted stratified analyses to explore the relation
between PUFAs and prostate cancer risk among subgroups,
including smoking status (ever vs never smokers), median age at
diagnosis (o62 vs X62 years), disease status (advanced vs non-
advanced prostate cancer), and method of detection (screen- vs
clinically-detected prostate cancer). Polytomous regression was
used to estimate adjusted stratum-specific ORs and 95% CIs for the
associations between PUFA-specific wPRSs and disease status and
method of prostate cancer detection. Statistically significant
differences between strata of each potential effect measure modifier
were assessed using the likelihood ratio test for the multiplicative
interaction term (for smoking status and age at diagnosis), and
using the test for homogeneity (for disease status and method of
detection). Advanced prostate cancer included those cases with
either Gleason scoreX8, died from prostate cancer, had metastatic
disease, or prostate-specific antigen levels 4100 ngml 1 at
diagnosis. We also compared the results for the associations
between the PUFA-specific wPRS and prostate cancer from the
pooled analysis using individual-level data to the summary
associations derived from meta-analyses of each PRACTICAL
study (Supplementary Figures 6–11). Analyses were conducted
using SAS version 9.4 (Cary, NC, USA), and STATA version 12.1
(College Station, TX, USA).
Sensitivity analyses. Several sensitivity analyses were conducted to
assess the robustness of our results. First, we assessed whether the
PUFA-specific wPRSs were associated with prostate cancer risk
factors, namely age, body mass index, prostate-specific antigen
levels, smoking, alcohol intake, family history of prostate cancer,
history of benign prostatic hyperplasia, history of prostatitis, and
physical activity levels. Only age was significantly associated with
most PUFA-specific wPRSs (with the exception of DHA), and
physical activity was associated with the wPRSs for DPA and DHA.
We compared models adjusting for different covariates; however,
our results did not change appreciably after controlling for age,
eight principal components for European ancestry, PRACTICAL
study site, or physical activity (Supplementary Table 1).
Summary statistics from the previous PUFA GWAS (Lemaitre
et al, 2011; Guan et al, 2014) were used in tandem with the
summary estimates from the PRACTICAL consortium to calculate
the Mendelian randomisation estimate using an inverse-variance
weighted meta-analysis approach (Burgess et al, 2013). We further
standardised the Mendelian randomisation ORs and 95% CIs to
represent an increase in prostate cancer risk per one standard
Table 1. Effect estimates for plasma phospholipid levels of polyunsaturated fatty acids (PUFAs, % of total fatty acids) for
genome-wide significant (Po5108), independent (r2 o0.1) genetic variants reported from previous GWAS
Chr SNP
GRCh37/
hg19
position Allelea EAF b s.e. P-value
% VEb
per
allele
% VE
per IVc
F-statistic
per IVd
Linoleic acid (LA, 18:2n6)
10 rs10740118 65101207 C/G 0.56 0.248 0.043 8.08109 0.2–0.7
11 rs174547 61570783 T/C 0.32 1.474 0.042 4.9810274 7.6–18.1
11 rs2727270 61603237 T/C 0.44 0.690 0.070 2.60 10 21 0.5–2.4
16 rs16966952 15135943 A/G 0.31 0.351 0.044 1.23 10 15 0.5–2.5 8.8–23.6e 1104–3533
Arachidonic acid (AA, 20:4n6)
11 rs174547 61570783 T/C 0.68 1.691 0.025 3.0010971 32.63
16 rs16966952 15135943 A/G 0.69 0.199 0.031 2.43 10 10 0.44 33.07 11302
a-Linolenic acid (ALA, 18:3n3)
11 rs174547 61570783 T/C 0.33 0.016 0.001 3.47 10 64 1.03 1.03 476
Eicosapentaenoic acid (EPA, 20:5n3)
6 rs3798713 11008622 C/G 0.43 0.035 0.005 1.93 10 12 0.36
11 rs174538 61560081 A/G 0.72 0.083 0.005 5.37 10 58 1.69 2.05 479
Docosapentaenoic acid (DPA, 22:5n3)
2 rs780094 27741237 T/C 0.41 0.017 0.003 9.04 10 09 0.46
6 rs3734398 10982973 T/C 0.43 0.040 0.003 9.61 10 44 2.74
11 rs174547 61570783 T/C 0.67 0.075 0.003 3.7910154 8.38 11.58 1997
Docosahexaenoic acid (DHA, 22:6n3)
6 rs2236212 10995015 C/G 0.57 0.113 0.014 1.26 10 15 0.65 0.65 299
Abbreviations: EAF¼ effect allele frequency; IV¼ instrumental variable; s.e.¼ standard error; SNP¼ single-nucleotide polymorphism.
aAllele associated with an increase in PUFA levels is in bold, and is considered the effect allele.
b% variation explained (VE)¼ (2 b2EAF (1EAF)/var(PUFA)) 100.
c% VE per IV¼ sum of the %VE per allele for each SNP included in the IV.
dF-statistic is a measure of the strength of the genetic instrument and is calculated as follows: (R2 (n-1-k))/((1-R2)  k), where R2¼% variation explained, n¼ sample size, k¼ total number of
instrumental variables.
eRanges for % VE per SNP and % VE IV as reported in Guan et al (2014).
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deviation increase for each PUFA-specific wPRS, thus representing
a standard deviation increase in percentage of PUFA levels per
total plasma fatty acids (Supplementary Table 2).
Assessing pleiotropy. Two data-driven approaches were used to
formally assess the impact of genetic pleiotropy on our results
using summary statistics. First, we assessed the impact of genetic
pleiotropy and potentially invalid instruments using Egger
regression (Bowden et al, 2015). This approach assesses the
validity of the genetic instrument and provides an estimate of
the average pleiotropic effect across genetic instruments used in the
instrument (Supplementary Table 2).
Second, given several variants were included in the different
PUFA-specific genetic instruments, we conducted a sensitivity
analysis to account for this potential pleiotropy. This method also
further evaluated the strength of the genetic instruments used in
our analysis. Using a weighted regression-based approach, the
association (Yg) between variant (g) and prostate cancer (Y) was
regressed on the association (Xg) between that same variant (g) and
the PUFA trait of interest (X), weighted by the inverse variance
(sYg
 2) (Burgess et al, 2015; Burgess and Thompson, 2015). This
approach accounts for the potential pleiotropy of variants used in
each instrument on other PUFA traits. Results from this sensitivity
analysis to account for potential pleiotropy and causal associations
between PUFA subtypes are presented in Supplementary Table 3.
RESULTS
In Table 1, we provide a list of PUFA-associated genetic variants
and their GWAS-reported results that were used to create the
PUFA-specific wPRSs. Each PUFA-specific instrument explanatory
variation ranged from 0.65% (for DHA) to B33% (for AA).
Because of the large size of the PRACTICAL consortium, the
F-statistic for all the genetic variants was large (all F-statistics were
410), indicating a strong genetic instrument for the PUFA
exposures of interest (Stock et al, 2002).
The associations between one standard deviation increase in
wPRSs with prostate cancer risk for the majority of PUFA-specific
wPRSs were null (Table 2). When stratified by age, modest
increases in prostate cancer risk were observed for AA (OR¼ 1.05,
95% CI¼ 1.02, 1.08), EPA (OR¼ 1.04, 95% CI¼ 1.01, 1.06), and
DPA (OR¼ 1.05, 95% CI¼ 1.02, 1.08) among men o62 years of
age; whereas a modest risk reduction was observed for LA
(OR¼ 0.95, 95% CI¼ 0.92, 0.98) and ALA (OR¼ 0.96, 95%
CI¼ 0.93, 0.98) among this same age group. No differences were
observed when stratified by smoking status (ever vs never
smokers), disease status (advanced vs non-advanced prostate
cancer), or method of detection (screen-detected vs clinically-
detected prostate cancer). When modeled using the restricted cubic
splines, the associations between the wPRS and prostate cancer risk
were also null (data not shown). The pooled results for the
association between PUFA-specific wPRSs and prostate cancer risk
were nearly identical to the summary estimate derived from fixed-
and random-effects meta-analyses of the wPRSs and prostate
cancer risk across studies included in the PRACTICAL consortium
(Supplementary Figures 6–11). Furthermore, our results did not
change after adjusting for different covariates, including age and
physical activity that were found to be associated with the PUFA-
specific wPRSs (Supplementary Table 1). We also conducted a
Mendelian randomisation analysis via the two-sample method
using summary statistics scaled per one standard deviation unit
increase (Supplementary Table 2), and the results were nearly
identical to those obtained from the individual-level analysis using
wPRSs.
The impact of pleiotropic variants on the Mendelian randomi-
sation estimate was assessed using two different approaches, Egger
regression and a weighted regression-based method. With the
exception of the wPRS for DPA (b0¼ 0.01304, Po0.0001), we did
not observe any statistically significant intercepts as an indication
of potential pleiotropic effects and an invalid instrument
(Supplementary Table 2). We also assessed the impact of
pleiotropic variants on other PUFA traits via the weighted
regression-based approach and, in general, observed little differ-
ence between the unadjusted models and models adjusted for
potential pleiotropic effects on other PUFA traits (Supplementary
Table 3). A 12% risk reduction (95% CI¼ 0.60, 1.29) for AA and a
10% increased risk (95% CI¼ 0.88, 1.36) for ALA were indicated
after adjusting for the potential pleiotropic effects of the
instrument on other PUFA traits; however, the confidence intervals
were imprecise.
DISCUSSION
We examined the association between genetically-predicted plasma
PUFA levels (via construction of PUFA-specific wPRSs) using
individual-level data and summary statistics for PUFAs in relation
to prostate cancer risk. Our findings suggest no overall association
between plasma PUFA levels and risk of developing prostate
cancer. However, a potential interaction with age (o62 vs X62
years of age) was observed.
Meta-analysis results from previous studies of Caucasian
populations reported a null association for studies examining
self-reported dietary intakes of long-chain o-3 PUFAs (summary
RR¼ 1.00, 95% CI¼ 0.93, 1.09), and a modest, but not statistically
significant, increased risk for studies examining biomarkers
(summary RR¼ 1.07; 95% CI¼ 0.94, 1.20) (Alexander et al,
2015). The meta-analysis also suggested prostate cancer risk
reductions from studies that examined DPA intake via self-report
(summary RR¼ 0.92; 95% CI¼ 0.71, 1.19) and biomarkers
(summary RR¼ 0.85, 95% CI¼ 0.72, 0.99). Results from another
meta-analysis of prospective studies reported null associations with
high intake of ALA in relation to prostate cancer risk (Carayol
et al, 2010). Although our results for the overall null association
were consistent with findings from previous studies as summarised
in the two meta-analyses described above, we found that the
association between PUFAs and prostate cancer risk may be
modified by age at onset. Stratification by age at onset may have
revealed the cumulative effect of PUFAs on prostate cancer risk.
Given germline genetic variation will not vary over time, and if we
assume that the wPRS is representative of a cumulative lifetime
exposure to PUFAs, then it is possible that a higher magnitude of
the effect would have been revealed for older men (e.g., increased
risk for o-6 would have been stronger and reduced risk would have
been lower for o-3 PUFAs among older men). However, our
results indicate modest increases in risks for LA and modest
reduced risks for long-chain o-3 PUFAs (EPA, DPA, and DHA)
among older men (X62 years of age) relative to younger men
(o62 years). It is also possible that prostate cancer cases diagnosed
ato62 years of age could reflect a more aggressive form of disease.
However, when we considered stratification by disease severity the
increased risks were not observed. Thus, additional research may
be needed to disentangle the effects of screening and the potential
for outcome misclassification of aggressive vs indolent prostate
cancer cases. For o-6 PUFAs, a systematic review reported no
strong positive association for AA (either dietary or biomarker) in
relation to prostate cancer risk (Sakai et al, 2012), nor was an
association observed in a meta-analysis of dietary LA intake and
prostate cancer risk (Zock and Katan, 1998).
Although our study was sufficiently large to detect associations
between PUFAs and prostate cancer incidence, several limitations
remain. First, Mendelian randomisation assumes that the genetic
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instrument is (1) associated with the exposure; (2) not associated
with any confounders of the exposure-outcome association; and
(3) independent of the outcome given the exposure and
confounders (i.e., the genetic instrument only affects the outcome
via the exposure of interest) (Burgess et al, 2015; Burgess and
Thompson, 2015). The validity of the Mendelian randomisation
estimate hinges on these assumptions. In our study, the F-statistics
for all the genetic instruments were large (410) indicating strong
genetic instruments that are associated with the exposure.
However, for many of the PUFA-specific instruments the
percentage of variation explained was low (o3%), and future
research investigations should identify additional variants to
incorporate into the genetic instruments to further improve the
instrument strength. Furthermore, the PUFA-specific genetic
instruments were not associated with potential confounders, with
the exception of physical activity for DPA and DHA. However,
adjustment for physical activity did not alter our conclusions, thus
providing additional evidence that the genetic instruments utilised
in this analysis are independent of confounders. The only potential
concern regarding the validity of the genetic instrument is the
possibility of unknown pleiotropic effects, which would violate the
aforementioned third assumption. Even though this analysis used
several common GWAS-identified variants in the PRS, there are
likely additional rare variants that were not included in this
analysis and have yet to be discovered. However, even with the
inclusion of potential rare variants, the percent variation explained
by the genetic instrument may not be vastly improved unless these
rare variants are found to have large effects. Further replication by
others is required to elucidate the true associations for other
PUFAs, including the long-chain o-3 PUFAs for which anti-
inflammatory action has been suggested by laboratory studies
(Berquin et al, 2011). Although we examined stratification by
disease status, the possibility for misclassification of aggressive vs
low-risk prostate cancer cases remains. Future advancements in
prostate cancer screening, via serum (i.e., prostate health index or
Kallikrein protein levels) or urinary (i.e., PCA3 or TMPRSS2-ERG
fusion) markers (Cuzick et al, 2014), may help to better separate
aggressive prostate cancer from low-risk indolent cases, which may
help to potentially reveal the benefits of long-chain o-3 PUFAs
among truly aggressive prostate cancers.
Our analysis has several strengths. First, we conducted analyses
using individual-level data, which allowed us to control for
potential confounders of the association between the wPRS and
prostate cancer risk, including principal components for European
ancestry. The individual-level analysis also allowed us to examine
effect measure modification by conducting stratified analyses.
Second, we conducted our analysis using a large sample of data
from the PRACTICAL consortium. Furthermore, we utilised
available summary statistics data from this large PRACTICAL
consortium and effect estimates from previous PUFA GWAS to
conduct a two-sample Mendelian randomisation analysis. Given
large sample sizes of these studies and the use of independent
variants in each genetic instrument, the Mendelian randomisation
estimate from the two-sample approach using summary statistics
will be equivalent to the Mendelian randomisation estimate from a
one-sample approach (via two-stage least-squares regression) with
available genetic and biomarker information (Haycock et al, 2016).
Although, we did not observe any substantial pleiotropic effects
when we conducted the weighted regression-based method
(Burgess et al, 2015; Burgess and Thompson, 2015) nor via Egger
regression (Bowden et al, 2015), we are unable to completely rule
out the impact of unknown pleiotropic effects that could reduce the
validity of the Mendelian randomisation estimate (in particular for
DPA, for which the Egger’s P-value was statistically significant).
Finally, the proportion of variation explained by the SNPs included
in the genetic instrument for several PUFAs (AA, LA, and DPA)
was relatively high compared with other Mendelian randomisation
studies examining other traits (Ehret et al, 2011; Ahmad et al,
2015). Thus, the Mendelian randomisation association may reflect
the true null association, but requires confirmation by others, using
instruments that include additional variants and explain an even
higher percentage of variation in fatty acid levels (especially for
those PUFAs for which the percentage of variation explained was
low).
In conclusion, using data from a large consortium, we report
an overall null association between PUFAs (both o-3 and o-6)
and prostate cancer risk. Specifically, we report no association for
AA in relation to prostate cancer incidence, for which the strength
of the instrument and proportion of variation explained were high.
However, increased risks were indicated for meno62 years of age
for genetically-predicted increases in long-chain o-6 (AA). Similar
increases were observed for long-chain o-3 PUFAs (EPA and
DPA) among this age group, which is contrary to what would be
expected, given the hypothesised anti-inflammatory action of long-
chain o-3 PUFAs. Future investigations into these different
associations by age at onset could help to elucidate the roles of
PUFAs in the aetiology of prostate cancer.
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